BRIEF published on 11/05/2024 at 10:12, 1 year 4 months ago Leadership Transition at PharmaSGP Holding SE: Peter Gerckens to Succeed Natalie Weigand as CEO Company Growth OTC Pharmaceuticals Peter Gerckens Natalie Weigand PharmaSGP Leadership Change
PRESS RELEASE published on 11/05/2024 at 10:07, 1 year 4 months ago CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 PharmaSGP Holding SE announces CEO change with Peter Gerckens succeeding Natalie Weigand on January 1, 2025. Smooth transition planned for internal succession Succession Plan CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
BRIEF published on 11/05/2024 at 10:07, 1 year 4 months ago Leadership Change at PharmaSGP Holding SE: Peter Gerckens Appointed CEO Leadership Transition CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
PRESS RELEASE published on 11/05/2024 at 10:02, 1 year 4 months ago EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer PharmaSGP Holding SE appoints Peter Gerckens as new CEO, succeeding Natalie Weigand. Gerckens, currently CCO, will assume the CEO position on January 1, 2025 Supervisory Board PharmaSGP Holding SE CEO Succession Peter Gerckens Natalie Weigand
BRIEF published on 10/01/2024 at 08:20, 1 year 5 months ago PharmaSGP Holding SE Acquires 477,701 Shares Through Repurchase Offer Share Buyback Treasury Shares Capital Reduction PharmaSGP Repurchase Offer
PRESS RELEASE published on 10/01/2024 at 08:15, 1 year 5 months ago PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer PharmaSGP Holding SE has purchased 477,701 own shares through public share repurchase offer. The company's acceptance ratio is approximately 80.37% Share Buyback Treasury Shares Public Offer PharmaSGP Holding Acceptance Ratio
BRIEF published on 09/12/2024 at 08:20, 1 year 6 months ago PharmaSGP Continues Dynamic Growth Path in First Half of 2024 Revenue Growth International Expansion PharmaSGP OTC Pharmaceuticals 2024 Financials
BRIEF published on 09/12/2024 at 08:15, 1 year 6 months ago PharmaSGP Holding SE Announces Share Repurchase Program Share Repurchase Acceptance Period PharmaSGP Holding SE 594,405 Shares EUR 21.45
PRESS RELEASE published on 09/12/2024 at 08:15, 1 year 6 months ago PharmaSGP continues dynamic growth path in the first half of 2024 PharmaSGP Holding SE reports dynamic growth with half-year revenues reaching €58.4 million, up 17.4% from last year. Management expects full-year revenues to range from €107.0m to €112.0m Revenues Germany Growth Internationalization PharmaSGP
PRESS RELEASE published on 09/12/2024 at 08:10, 1 year 6 months ago EQS-Adhoc: PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares PharmaSGP Holding SE announces public share repurchase offer to buy back own shares for up to 594,405 shares, with acceptance period from September 13 to 26, 2024 Acceptance Period 2024 PharmaSGP Holding SE 594,405 Shares Share Repurchase Offer
Published on 03/20/2026 at 03:10, 7 hours 51 minutes ago Future Fuels Announces Filing of Amended and Restated Life Offering Document
Published on 03/20/2026 at 00:20, 10 hours 41 minutes ago Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A
Published on 03/20/2026 at 00:20, 10 hours 41 minutes ago Reeflex Solutions Inc. Announces Revocation of Management Cease Trade Order
Published on 03/19/2026 at 21:16, 13 hours 45 minutes ago Unusual Machines, Inc. Announces Proposed Public Offering
Published on 03/19/2026 at 14:20, 20 hours 41 minutes ago CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/20/2026 at 10:25, 35 minutes ago EQS-Adhoc: WashTec AG: Announcement of dividend proposal
Published on 03/20/2026 at 10:00, 1 hour ago SWI Group secures €260M capital increase in relation to the expansion to North America of its AI & data center strategy
Published on 03/20/2026 at 09:46, 1 hour 15 minutes ago EQS-Adhoc: Aumann has announced its preliminary figures for 2025, proposed a dividend of €0.25 per share and expects an EBITDA margin of 6 to 8% for 2026, despite a decline in revenue to around €160 Million
Published on 03/20/2026 at 09:30, 1 hour 30 minutes ago Tourism Authority of Thailand invites global travellers to rediscover balance through 'Healing Journey Thailand' campaign.
Published on 03/19/2026 at 18:00, 17 hours 1 minute ago Filing of the 2025 Universal Registration Document
Published on 03/19/2026 at 08:45, 1 day 2 hours ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 1 day 4 hours ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
